Written evidence for the Genomics and Genome-Editing Inquiry of the House of Commons Science and Technology Committee
By Edward Hockings and Lewis Coyne,
Ethics and Genetics [cites CGS]
| 01. 20. 2017
KEY POINTS
- UK biosciences policy has become increasingly motivated by economic considerations in recent years, at the expense, we believe, of substantive public consultation and broader deliberation
- Freedom of Information requests show that the 100,000 Genome Project misinformed participants and the public as to the nature of access to genomic data granted to third parties
- Genome editing raises major ethical concerns which require comparable public deliberation, prior to which all further research should be prohibited
- 1.Introduction
Three years have passed since the government revealed its plans to sequence 100,000 genomes. The 100,000 Genome Project is expected to achieve that goal later this year. There is reason to be optimistic about it being of value, scientifically and clinically. There are also, however, reasons to be concerned about both the Genome Project and other areas of the developing fields of genomic medicine. In the following we outline some of those reasons.
- 2.Responsible Governance of the Biosciences
The 100,000 Genome Project forms part of a recent (post-2010) trend in the UK’s biosciences policy. Example initiatives include the integration of personalised medicine in mainstream...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jonquilyn Hill, Vox | 10.18.2026
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...